Bavarian Nordic A/S (LON:0DPB)

Market Cap	2.14B
Revenue (ttm)	698.80M
Net Income (ttm)	148.16M
Shares Out	n/a
EPS (ttm)	1.86
PE Ratio	14.45
Forward PE	12.17
Dividend	n/a
Ex-Dividend Date	n/a

Volume	191,926
Average Volume	177,838
Open	238.05
Previous Close	236.71
Day's Range	235.50 - 238.00
52-Week Range	100.05 - 295.40
Beta	1.20
RSI	81.60
Earnings Date	Aug 22, 2025

About Smartsheet

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 1,605
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0DPB

Financial Performance

In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.